Faron, etusivu

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 04, 2026 at 15:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 04/06/2026
6. Date on which issuer notified (DD/MM/YYYY): 04/06/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 10.33% 13.84% 24.17% 49,884,320
Position of previous notification (if
applicable)		 9.55% 15.44% 24.99%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 21,324,320 28,560,000 10.33% 13.84%
SUBTOTAL 8. A 49,884,320 24.17%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 11,760,000 5.7%
Convertible Bond 12/02/2028 Anytime until maturity 16,800,000 8.14%
SUBTOTAL 8. B 1 28,560,000 13.84%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 10.33% 13.84% 24.17%
CVI Investments, Inc. 10.33% 13.84% 24.17%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 04.06.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | June 01, 2026 at 15:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 28/05/2026
6. Date on which issuer notified (DD/MM/YYYY): 29/05/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 8.98% 15.44% 24.42% 49,596,067
Position of previous notification (if
applicable)		 9.55% 15.44% 24.99%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 18,236,067 31,360,000 8.98% 15.44%
SUBTOTAL 8. A 49,596,067 24.42%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 13,440,000 6.62%
Convertible Bond 12/02/2028 Anytime until maturity 17,920,000 8.83%
SUBTOTAL 8. B 1 31,360,000 15.44%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 8.98% 15.44% 24.42%
CVI Investments, Inc. 8.98% 15.44% 24.42%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 29.05.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | May 28, 2026 at 16:00:00 EEST

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FIN-FSA)
1. Identity of the issuer:
Faron Pharmaceuticals Oy
2. Reason for the notification (please tick the appropriate box or boxes):

☐ An acquisition or disposal of shares or voting rights
☒ An acquisition or disposal of financial instruments
☐ An event changing the breakdown of shares or voting rights
☐ Other (please specify): Click here to enter text.
3. Details of person subject to the notification obligation:
Name:
Bank of America Corporation		 City and country of residence:
Wilmington, DE, Unites States of America
4. Full name of shareholder(s) (if different from 3.):
–
5. Date on which the threshold was crossed or reached:
26.5.2026
6. Total positions of person(s) subject to the notification obligation:
% of shares and voting rights
(total of 7.A)		 % of shares and voting rights through financial instruments
(total of 7.B)		 Total of both in % (7.A + 7.B) Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached 0.10 9.36 9.46 203,045,511
Position of previous notification (if applicable) n/a n/a n/a
7. Notified details of the resulting situation on the date on which the threshold was crossed or reached:
A: Shares and voting rights
Class/type of
shares
ISIN code (if possible)		 Number of shares and voting rights % of shares and voting rights
Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)		 Direct
(SMA 9:5)		 Indirect
(SMA 9:6 and 9:7)
FI4000153309 0 207,708 0 0.10
– – – – –
– – – – –
SUBTOTAL A 207,708 0.10
B: Financial Instruments according to SMA 9:6a
Type of financial instrument Expiration
date		 Exercise/
Conversion Period		 Physical or cash settlement Number of shares and voting rights % of shares and voting rights
Rights of Use n/a n/a n/a 18,798,276 9.26
Swaps 15/10/2027 n/a Cash 201,276 0.10
SUBTOTAL B 18,999,552 9.36

8. Information in relation to the person subject to the notification obligation (please tick the applicable box):

☐ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

☒ Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity:
Name % of shares and voting rights % of shares and voting rights through financial instruments Total of both
Bank of America Corporation Click here to enter text. Click here to enter text. Click here to enter text.
NB Holdings Corporation Click here to enter text. Click here to enter text. Click here to enter text.
BofAML Jersey Holdings Limited Click here to enter text. Click here to enter text. Click here to enter text.
BofAML EMEA Holdings 2 Limited Click here to enter text. Click here to enter text. Click here to enter text.
ML UK Capital Holdings Limited

Merrill Lynch International

Bank of America Corporation

NB Holdings Corporation

BAC North America Holding Company

Bank of America, National Association

Bank of America Coporation

NB Holdings Corporation

BofA Securities, Inc

 Click here to enter text.

9.26%

9.26%
9. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of Click here to enter a date.
10. Additional information:
–

Done at London, United Kingdom on 27.5.2026.

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | May 18, 2026 at 09:00:00 EEST

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: Decrease of holdings
3. Details of person subject to the notification obligation iv
Name Blood Cancer United, Inc.
City and country of registered office (if applicable) Washington, D.C., United States of America
4. Full name of shareholder(s) (if different from 3.) v
Name TAP BCU Faron, LLC
City and country of registered office (if applicable) Newark, Delaware, United States of America
5. Date on which the threshold was crossed or reached vi: 15/04/2026
6. Date on which issuer notified (DD/MM/YYYY): 14/05/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 3.47% 3.47% 7,037,426
Position of previous notification (if
applicable)
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 7,037,426 3.47%
SUBTOTAL 8. A 7,037,426 3.47%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv		 X
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Blood Cancer United, Inc. 100% owner of TAP BCU, LLC 0% 0%
TAP BCU, LLC. 100% owner of TAP BCU Faron, LLC 0% 0%
TAP BCU Faron, LLC, 3.47% 3.47%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Providing information directly to the Company as a result of meeting the threshold in the Company’s Arti-cles of Association (does not meet the AIM regulatory notification threshold).

Gordon G. Miller, Jr. (“JR Miller”), Executive Vice President & Chief Financial Officer Blood Cancer United, Inc. and authorized controlling person with respect to:

Blood Cancer United, Inc., TAP BCU, LLC and TAP BCU Faron, LLC
TAP BCU Faron, LLC, c/o Blood Cancer United, Inc. 1201 15th Street N.W., Suite 410, Washington, D.C. 20005 U.S.A.

+1.860.488.1774
Jr.Miller@bloodcancerunited.org

3.47% of shares and voting rights is as per Faron Pharmaceuticals Ltd. request to include Treasury Shares in the denominator. The percentage is 3.527% if exclude Treasury Shares.
Place of completion Blood Cancer United, Inc. Washington, D.C. U.S.A.
Date of completion 14/05/2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | May 05, 2026 at 10:30:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 30/04/2026
6. Date on which issuer notified (DD/MM/YYYY): 04/05/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 9.55% 15.44% 24.99% 50,753,166
Position of previous notification (if
applicable)		 10.00% 15.44% 25.44%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 19,393,166 31,360,000 9.55% 15.44%
SUBTOTAL 8. A 50,753,166 24.99%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 13,440,000 6.62%
Convertible Bond 12/02/2028 Anytime until maturity 17,920,000 8.83%
SUBTOTAL 8. B 1 31,360,000 15.44%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 9.55% 15.44% 24.99%
CVI Investments, Inc. 9.55% 15.44% 24.99%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 04.05.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | April 22, 2026 at 14:30:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 17/04/2026
6. Date on which issuer notified (DD/MM/YYYY): 20/04/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 10.00% 15.44% 25.44% 51,660,099
Position of previous notification (if
applicable)		 10.13% 15.44% 25.58%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
20,300,099 31,360,000 10.00% 15.44%
SUBTOTAL 8. A 51,660,099 25.44%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 13,440,000 6.62%
Convertible Bond 12/02/2028 Anytime until maturity 17,920,000 8.83%
SUBTOTAL 8. B 1 31,360,000 15.44%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 10.00% 15.44% 25.44%
CVI Investments, Inc. 10.00% 15.44% 25.44%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 20.04.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | April 20, 2026 at 10:15:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 15/04/2026
6. Date on which issuer notified (DD/MM/YYYY): 15/04/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 10.13% 15.44% 25.58% 51,929,014
Position of previous notification (if
applicable)		 8.37% 16.82% 25.19%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 20,569,014 31,360,000 10.13% 15.44%
SUBTOTAL 8. A 51,929,014 25.58%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 13,440,000 6.62%
Convertible Bond 12/02/2028 Anytime until maturity 17,920,000 8.83%
SUBTOTAL 8. B 1 31,360,000 15.44%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 10.13% 15.44% 25.58%
CVI Investments, Inc. 10.13% 15.44% 25.58%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 15.04.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | April 20, 2026 at 10:00:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals OY
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer X
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights X
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii:
3. Details of person subject to the notification obligation iv
Name Heights Capital Management, Inc.
City and country of registered office (if applicable) San Francisco, California
4. Full name of shareholder(s) (if different from 3.) v
Name CVI Investments, Inc.
City and country of registered office (if applicable) Cayman Islands
5. Date on which the threshold was crossed or reached vi: 14/04/2026
6. Date on which issuer notified (DD/MM/YYYY): 14/04/2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 8.37% 16.82% 25.19% 51,156,163
Position of previous notification (if
applicable)		 – 6.70% 6.70%
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 16,996,163 34,160,000 8.37% 16.82%
SUBTOTAL 8. A 51,156,163 25.19%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
Convertible Bond 08/02/2027 Anytime until maturity 15,120,000 7.45%
Convertible Bond 12/02/2028 Anytime until maturity 19,040,000 9.38%
SUBTOTAL 8. B 1 34,160,000 16.82%
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Heights Capital Management, Inc. 8.37% 16.82% 25.19%
CVI Investments, Inc. 8.37% 16.82% 25.19%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
None
Place of completion London, United Kingdom
Date of completion 14.04.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | April 16, 2026 at 18:00:00 EEST

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer x
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights x
Other (please specify) iii: Dividend payments in kind.
3. Details of person subject to the notification obligation iv
Name Timo Syrjälä
City and country of registered office (if applicable) Monaco
4. Full name of shareholder(s) (if different from 3.) v
Name Acme Investments SPF Sarl
City and country of registered office (if applicable) Luxembourg
5. Date on which the threshold was crossed or reached vi: 15.4.2026
6. Date on which issuer notified (DD/MM/YYYY): 16.4.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 7.77% 15.509.433
Position of previous notification (if
applicable)		 12.69% 14.697.112
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 5.949.320 9.560.113 2.98% 4.79%
SUBTOTAL 8. A 15.509.433

7.77%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv		 X
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct) 2.98% 2.98%
Acme Investments SPF Sarl (Indirect) 4.79% 4.79%
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information Faron share issue during April 2026
Place of completion Monaco
Date of completion 16.4.2026

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Faron Pharmaceuticals Ltd | Company announcement | March 24, 2026 at 18:30:00 EET

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Faron Pharmaceuticals Ltd
1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate)
Non-UK issuer x
2. Reason for the notification (please mark the appropriate box or boxes with an “X”)
An acquisition or disposal of voting rights x
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify) iii: Dividend payments in kind. x
3. Details of person subject to the notification obligation iv
Name Timo Syrjälä
City and country of registered office (if applicable) Monaco
4. Full name of shareholder(s) (if different from 3.) v
Name Acme Investments SPF Sarl
City and country of registered office (if applicable) Luxembourg
5. Date on which the threshold was crossed or reached vi: 20.03.2026
6. Date on which issuer notified (DD/MM/YYYY): 23.03.2026
7. Total positions of person(s) subject to the notification obligation
% of voting rights attached to shares (total of 8. A) % of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)		 Total of both in % (8.A + 8.B) Total number of voting rights held in issuer (8.A + 8.B) vii
Resulting situation on the date on which threshold was crossed or reached 12.69% 14.697.112
Position of previous notification (if
applicable)		 13.90% 16.093.129
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii
A: Voting rights attached to shares
Class/type of
shares
ISIN code (if possible)		 Number of voting rights ix % of voting rights
Direct
(DTR5.1)		 Indirect
(DTR5.2.1)		 Direct
(DTR5.1)		 Indirect
(DTR5.2.1)
FI4000153309 5.621.095 9.076.017 4.85% 7.84%
SUBTOTAL 8. A 14.697.112 12.69%
B 1: Financial Instruments according to DTR5.3.1R (1) (a)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Number of voting rights that may be acquired if the instrument is
exercised/converted.		 % of voting rights
SUBTOTAL 8. B 1
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)
Type of financial instrument Expiration
date x		 Exercise/
Conversion Period xi		 Physical or cash
Settlement xii		 Number of voting rights % of voting rights
SUBTOTAL 8.B.2
9. Information in relation to the person subject to the notification obligation (please mark the
applicable box with an “X”)
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii
Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity (please add additional rows as necessary) xiv		 X
Name xv % of voting rights if it equals or is higher than the notifiable threshold % of voting rights through financial instruments if it equals or is higher than the notifiable threshold Total of both if it equals or is higher than the notifiable threshold
Timo Syrjälä (Direct) 4.85% 4.85%
Acme Investments SPF Sarl (Indirect) 7.84 % 7.84 %
10. In case of proxy voting, please identify:
Name of the proxy holder
The number and % of voting rights held
The date until which the voting rights will be held
11. Additional information xvi
Place of completion Monaco
Date of completion 23.3.2026
Back to top